The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation
Honan will lead the company in identifying and executing acquisitions that complement Emmes’ existing strong federal government client base, expand its biopharma portfolio, enhance its technology offerings, and broaden its global reach
Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.
This partnership stemmed from a successful customer-supplier relationship spanning several years.
The investment will enable the company to enter European markets as well as enhance margins in current markets
The new center will focus on supporting the clinical trials clients who are developing cell and gene therapies
35 million mosquito nets supplied to countries in sub-Saharan Africa through partners
Soluplus branded excipient play a critical role in enabling the drug development process for poorly soluble active pharmaceutical ingredients
Expanded capacity in Nansha, China will support mid-scale manufacturing to ensure a smooth transition between early-phase and large-scale commercial production
Subscribe To Our Newsletter & Stay Updated
